{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:05:43Z","timestamp":1784667943477,"version":"3.55.0"},"reference-count":0,"publisher":"Akademizdatcenter Nauka","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Epidermal growth factor receptor (EGFR) is one of the most studied proteins in the world. A genuine interest in EGFR is related to its key role in the main conserved signalling pathways responsible for cell growth, survival, and proliferation. Dysregulation of these signalling pathways leads to malignant transformation, promotion of tumour progression, cell migration and invasion. In this regard, EGFR is considered as one of the main targets for anticancer drugs development. Despite several generations of novel anti-EGFR drugs have been successfully developed, acquisition of drug resistance, as well as the mutation status of downstream effector protein KRAS, significantly reduce tumour response to the therapy. This review focuses on the current approaches of anti-EGFR therapy. Here, we will describe drugs aimed at blocking EGFR-mediated signalling, such as monoclonal antibodies, tyrosine kinase inhibitors. Mechanisms of acquired resistance to anti-EGFR therapy will be reviewed, and combination treatment strategies will be proposed. Finally, we will discuss promising antitumor agents including immunotoxins and ribonucleases (RNases) of various origins.<\/jats:p>","DOI":"10.7868\/s3034555325060034","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:28:18Z","timestamp":1774621698000},"page":"909","source":"Crossref","is-referenced-by-count":1,"title":["Novel Approaches to anti-EGFR Therapy"],"prefix":"10.7868","volume":"59","author":[{"given":"E.V.","family":"Dudkina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Nadyrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Luginskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Kosnyrev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.","family":"Ulyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.N.","family":"Ilinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4687","container-title":["\u041c\u043e\u043b\u0435\u043a\u0443\u043b\u044f\u0440\u043d\u0430\u044f \u0431\u0438\u043e\u043b\u043e\u0433\u0438\u044f \/ Molecular Biology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:28:18Z","timestamp":1774621698000},"score":1,"resource":{"primary":{"URL":"https:\/\/molbioras.ru\/s3034555325060034-1\/?version_id=126232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.7868\/s3034555325060034","relation":{},"ISSN":["3034-5553"],"issn-type":[{"value":"3034-5553","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}